Inhibrx Biosciences Inc (INBX) AI Stock Analysis

• Market Cap: $189.78M
• Dividend Yield: N/A
• Average Volume (3M): 91.14K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.92
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 170
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 14,475,904
• 10 Day Avg. Volume: 102,882
• 30 Day Avg. Volume: 91,145
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 133.91
• Price to Cash Flow (P/CF): -1.60
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

Inhibrx Biosciences Inc's overall stock score reflects significant financial challenges, with persistent losses and negative cash flows as the most critical factors. While recent positive corporate events, including promising trial results and securing substantial financing, provide some optimism, the lack of upward technical momentum and unclear valuation metrics limit the stock's attractiveness at this time. Strategic improvements in financial performance are needed to bolster investor confidence and enhance stock potential.

Positive Factors

Clinical Trials

Ozekibart in combination with FOLFIRI shows a promising 40% ORR in 2L+ CRC patients.

Regulatory Approval

The FDA gave the green light for a registrational study of ozekibart against placebo for unresectable/metastatic chondrosarcoma.

Negative Factors

Safety Concerns

Safety concerns are highlighted by a 31% ALT increase and a patient's death due to neutropenic sepsis.

Inhibrx Biosciences Inc Business Overview & Revenue Model

Company Description

Inhibrx Biosciences Inc (INBX) is a biotechnology company focused on the discovery, development, and commercialization of protein-based therapeutics. The company operates primarily in the biopharmaceutical sector, with a focus on developing a pipeline of proprietary therapeutic candidates for the treatment of cancer and other serious diseases. Inhibrx leverages its proprietary protein engineering technologies to create novel biologics that aim to address unmet medical needs.

How the Company Makes Money

Inhibrx Biosciences Inc generates revenue primarily through collaborative research and development agreements, as well as potential milestone payments and royalties from its partners. The company may enter into strategic partnerships with larger pharmaceutical companies to co-develop or out-license its drug candidates, which can provide upfront payments and funding for research and clinical trials. Additionally, as its therapeutic candidates progress through clinical trials and receive regulatory approvals, Inhibrx has the potential to earn revenue from product sales. However, given the nature of biotechnology firms, significant revenue from product sales is typically realized only after successful commercialization of its therapies.

Inhibrx Biosciences Inc Financial Statement Overview

Summary

Inhibrx Biosciences Inc faces significant financial challenges across all verticals. The company shows persistent losses and negative cash flows, which could hinder growth and sustainability. Improvements in revenue generation and cost management are crucial to strengthen financial stability and investor confidence.

Income Statement

The company's income statement shows significant challenges, with consistently negative EBIT and net income indicating ongoing losses. The gross profit margin is low, and the net profit margin is negative, reflecting inadequate revenue to cover expenses. Revenue growth is inconsistent, with recent declines. These factors highlight the need for strategic adjustments to improve profitability.

Balance Sheet

The balance sheet reveals a moderately leveraged position with a debt-to-equity ratio that indicates reliance on debt financing. However, a positive equity ratio suggests some stability. The ROE is not meaningful due to negative net income. The company needs to manage its liabilities effectively to improve financial health.

Cash Flow

Cash flow analysis indicates substantial negative operating and free cash flow, demonstrating cash burn issues. The operating cash flow to net income ratio is negative, highlighting inefficiencies in converting income into cash. Free cash flow growth is not present, emphasizing the need for improved cash management and operational efficiency.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
1.73M	1.80M	2.18M	7.13M	12.81M	9.09M
	Gross Profit
601.00K	609.00K	-668.00K	4.44M	-60.69M	-38.81M
	EBIT
-369.81M	-219.22M	-129.12M	-76.56M	-67.44M	-43.71M
	EBITDA
1.66B	-206.69M	-125.82M	-76.56M	-67.44M	-42.60M
	Net Income Common Stockholders
1.64B	-241.36M	-145.23M	-81.77M	-75.64M	-51.40M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
6.24M	277.92M	273.87M	131.30M	128.66M	11.54M
	Total Assets
24.02M	307.89M	290.88M	150.45M	143.74M	26.49M
	Total Debt
16.64M	210.14M	202.07M	70.47M	37.45M	41.73M
	Net Debt
10.40M	-67.78M	-71.80M	-60.83M	-91.21M	30.19M
	Total Liabilities
84.61M	264.39M	232.82M	98.07M	68.27M	120.06M
	Stockholders Equity
-60.58M	43.50M	58.06M	52.38M	75.47M	-93.57M
Cash Flow		Free Cash Flow
-213.53M	-197.90M	-115.99M	-81.19M	-49.33M	-33.89M
	Operating Cash Flow
-207.51M	-193.31M	-115.30M	-80.32M	-47.97M	-32.08M
	Investing Cash Flow
-6.02M	-4.59M	-686.00K	-809.00K	-1.36M	-1.81M
	Financing Cash Flow
72.54M	201.96M	258.55M	83.77M	166.46M	43.33M

Inhibrx Biosciences Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$4.14B	-16.38	-7.15%	4.57%	31.91%	-52.34%
NKTR	47 Neutral	$151.26M	―	-161.63%	―	5.53%	46.09%
INBX	42 Neutral	$189.78M	―	919.96%	―	―	―
FATE	42 Neutral	$115.74M	―	-54.21%	―	-78.55%	-0.92%
AGEN	38 Underperform	$50.44M	―	260.68%	―	59.00%	32.67%
XNCR	37 Underperform	$960.40M	―	-34.74%	―	-36.72%	-64.37%

Inhibrx Biosciences Inc Corporate Events

Inhibrx Biosciences Reports Promising Trial Results for INBRX-109

On January 21, 2025, Inhibrx Biosciences announced preliminary results from a Phase 1 trial of their therapeutic candidate ozekibart (INBRX-109) in combination with FOLFIRI for treating advanced colorectal adenocarcinoma. The trial showed promising efficacy, with one complete response and three partial responses among patients, and manageable safety profiles where most adverse events were low-grade. Encouraged by these results, Inhibrx has initiated an expansion cohort to further validate the findings, with results expected in the third quarter of 2025. This development underscores ozekibart’s potential in providing clinical benefits in heavily pretreated populations, positioning Inhibrx as an emerging player in the oncology therapeutics landscape.

Inhibrx Biosciences Secures $150M Loan for Growth

Inhibrx Biosciences, Inc. announced a loan and security agreement with Oxford Finance LLC, securing a term loan facility of up to $150 million, with an initial funding of $100 million. The agreement, which includes issuing warrants to the lenders, provides Inhibrx with strategic financial flexibility to advance its clinical programs, INBRX-109 and INBRX-106, both expected to have key data readouts in 2025. This financial support is anticipated to bolster Inhibrx’s position in the biopharmaceutical industry, aiding in the further development of its innovative therapeutic pipeline.